BioNexus Gene Lab Corp. reported its financial results for the second quarter and first half of 2025, revealing a total revenue of $2.26 million for the three months ending June 30, 2025, a 14.5% increase from $1.97 million in the same period of 2024. For the six-month period, revenue reached $4.40 million, slightly up from $4.36 million year-over-year. The company experienced a gross profit of $368,022 for the second quarter, marking a 27.5% increase compared to $288,720 in the prior year. However, the company reported a net loss of $616,172 for the quarter, a significant decline from a profit of $199,104 in Q2 2024, primarily due to increased operating expenses and a decrease in other income.
The financial performance reflects a notable shift in operational dynamics. Operating expenses surged by 56.5% to $1.19 million in Q2 2025, driven largely by a substantial increase in sales and marketing costs, which rose to $608,427 from $136,494 in the previous year. This increase is attributed to heightened compensation expenses and investments in channel development. Additionally, the company reported a significant decrease in other income, which fell to $209,461 from $730,105, largely due to a normalization in the reversal of expected credit losses.
In terms of strategic developments, BioNexus has been actively pursuing growth initiatives, including a strategic partnership with ML Tech to enhance its Ethereum-based growth strategies and a non-binding term sheet with Fidelion Diagnostics for exclusive commercialization rights in Southeast Asia. The company is also transitioning Chemrex Corporation into a biotechnology-focused contract development and manufacturing organization (CDMO), which is expected to gradually shift its revenue mix towards higher-margin biotech contracts by 2026.
Operationally, BioNexus reported a decrease in customer engagement metrics, particularly in its genomic screening services segment, which saw a revenue drop due to fewer client referrals and equipment unavailability. In contrast, the trading of industrial chemicals segment showed resilience, contributing the majority of revenue. The company’s total assets decreased to $9.42 million as of June 30, 2025, down from $10.43 million at the end of 2024, while total liabilities also declined to $1.90 million from $2.11 million, indicating a strengthening balance sheet.
Looking ahead, BioNexus aims to leverage its clean balance sheet and low compliance costs to pursue selective mergers and acquisitions that align with its long-term strategy. The company is also exploring additional capital-raising mechanisms to support its growth initiatives, particularly in digital healthcare and decentralized financial infrastructure. Management remains optimistic about the future, emphasizing a commitment to operational efficiency and innovation to enhance shareholder value.
About BioNexus Gene Lab Corp
BioNexus Gene Lab Corp. operates through two subsidiaries: Chemrex, which distributes fiber-reinforced polymer (FRP) chemical raw materials to manufacturers in Southeast Asia, and MRNA Scientific, which develops non-invasive RNA-based liquid biopsy tests for early detection of cancers and inflammatory diseases. The company serves industrial manufacturers and healthcare providers, leveraging proprietary genomic screening technology and extensive regional distribution to offer specialized diagnostics and chemical materials with technical expertise and broad product ranges.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.